GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,413.00p
   
  • Change Today:
    -8.50p
  • 52 Week High: 1,671.00
  • 52 Week Low: 1,264.00
  • Currency: UK Pounds
  • Shares Issued: 4,083.56m
  • Volume: 9,609,547
  • Market Cap: £57,701m
  • RiskGrade: 129

US FDA approves new format of GSK's Shingrix

By Josh White

Date: Thursday 17 Jul 2025

LONDON (ShareCast) - (Sharecast News) - GSK announced on Thursday that it has received approval from the US Food and Drug Administration for a new prefilled syringe presentation of its shingles vaccine, Shingrix.
The FTSE 100 company said the change eliminated the need for reconstitution prior to administration, streamlining the process for healthcare providers.

It said the current format of Shingrix required healthcare professionals to combine a lyophilised antigen with a liquid adjuvant before injection.

The newly-approved version simplifies that by offering a ready-to-use format, following data demonstrating technical comparability with the original presentation.

GSK said the prefilled syringe would be available under the same indications as the original version.

It is approved in the US for adults aged 50 and over, and for those aged 18 and over who are immunocompromised due to disease or therapy.

The CDC recommends a two-dose regimen of Shingrix in these populations.

"At GSK, we are committed to advancing scientific innovation and delivering practical solutions that address the needs of the healthcare community," said Tony Wood, chief scientific officer at GSK.

"This new presentation of Shingrix was developed to streamline the vaccination process, supporting healthcare professionals to provide protection against shingles, a disease that one in three US adults will develop in their lifetime."

The new presentation was also under review by the European Medicines Agency, with filing accepted in January.

GSK said it was considering submissions in additional markets as part of its wider push to expand adult immunisation.

It said shingles affects around one million Americans annually and is caused by the reactivation of the varicella-zoster virus.

While not all who carry the virus will develop shingles, risk increases with age as immune function declines.

At 0902 BST, shares in GSK were down 0.46% at 1,415p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,413.00p
Change Today -8.50p
% Change -0.60 %
52 Week High 1,671.00
52 Week Low 1,264.00
Volume 9,609,547
Shares Issued 4,083.56m
Market Cap £57,701m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
49.5% below the market average49.5% below the market average49.5% below the market average49.5% below the market average49.5% below the market average
56.52% above the sector average56.52% above the sector average56.52% above the sector average56.52% above the sector average56.52% above the sector average
Price Trend
9.38% above the market average9.38% above the market average9.38% above the market average9.38% above the market average9.38% above the market average
43.48% above the sector average43.48% above the sector average43.48% above the sector average43.48% above the sector average43.48% above the sector average
Income
72.73% above the market average72.73% above the market average72.73% above the market average72.73% above the market average72.73% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
31.34% below the market average31.34% below the market average31.34% below the market average31.34% below the market average31.34% below the market average
62.5% below the sector average62.5% below the sector average62.5% below the sector average62.5% below the sector average62.5% below the sector average

What The Brokers Say

Strong Buy 3
Buy 2
Neutral 16
Sell 3
Strong Sell 0
Total 24
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q1 Q4
Ex-Div 15-May-25 20-Feb-25
Paid 10-Jul-25 10-Apr-25
Amount 16.00p 16.00p

Trades for 17-Jul-2025

Time Volume / Share Price
16:24 0 @ 1,411.00p
16:22 0 @ 1,411.00p
16:22 0 @ 1,411.00p
16:22 0 @ 1,411.00p
16:12 0 @ 1,408.50p

GSK Key Personnel

CEO Emma Walmsley

Top of Page